Eric Langer | 10/23/2014
Biopharmaceutical companies that get stuck with legacy technologies, including older stainless steel equipment, and older processes, end up watching as competitors transition to more efficient, cost-effective platforms. But this isn’t just a cost-of-production issue; it goes to more strategic factors like being able to even participate in the emerging biosimilars markets, as well as being able to participate in global emerging economies.
Our 11thAnnual Report of Biopharmace...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
SmartLab Exchange Europe
February 25 - 26, 2025
Novotel Amsterdam City, Netherlands
Register Now |
View Agenda |
Learn More
SmartLab Exchange USA 2025
08 - 09 April, 2025
Le Méridien, Fort Lauderdale, Florida, USA
Register Now |
View Agenda |
Learn More